SEC Filings
AstraZeneca Wins EU Committee Backing For Blood-Pressure Drug Already Approved In The US
Baxfendy could become the EU's first aldosterone synthase inhibitor for patients whose blood pressure remains uncontrolled on other medicines.
AstraZeneca (AZN) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
Baxfendy could become the EU's first aldosterone synthase inhibitor for patients whose blood pressure remains uncontrolled on other medicines.
SEC Filings
The treatment expands Imfinzi's reach to patients unable or unwilling to take cisplatin, but severe adverse events were more common.
SEC Filings
The rare-disease treatment improved patients’ daily activities versus placebo, with benefits starting in week one.
Markets
The drugmaker reconfirmed its 2026 outlook and launched a savings program as oncology offset generic competition for Farxiga.
Earnings
Oncology revenue climbed 17% to $7,765 million in the third quarter, and the drugmaker kept its 2026 outlook unchanged.
SEC Filings
The European Commission cleared the cancer drug for HER2-positive early breast cancer patients with residual disease, triggering a milestone payment.
SEC Filings
The approval rests on a lab marker, not proof of slower kidney decline, and kidney-function data from the I CAN trial are still pending.